Author name: Leonardo Arias

Bill Shields, who led transcatheter mitral and tricuspid therapies at Medtronic, has joined Versa Vascular, developer of a valve repair treatment.

Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day for the Prader-Willi syndrome community.

Philips framed the revised agreement with Exor, the holding company of Italy’s billionaire Agnelli family, as evidence of confidence in its strategy.

It’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in depression.

The multiyear partnership will connect Abbott’s over-the-counter Lingo sensor and the Google Health app. 

The company says its patient portal should help translate medical jargon into plain language. It’s Oracle’s latest move to stand out in the competitive EHR market.

Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.

Beyond the legal action, Eli Lilly is calling on healthcare providers, regulatory authorities, online platforms and even logistics companies to help stem the illegal sale of its next-generation asset for weight loss.

The libertarian think tank analyzed almost 130 studies digging into the controversial laws, which require providers to get state approval before building facilities or adding new services. What it found wasn’t good.

BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.